The Latest Breaking News from Moderna

Moderna's Personalised Cancer Vaccine Clears Phase 3: How Soon Could Patients Receive It?

Moderna and Merck's personalised cancer vaccine shows positive Phase 3 results, reducing melanoma recurrence risk. Regulatory approval is pending, with potential market availability by 2027.

International Business Times UK · Aug 20

Moderna, Merck breakthrough could usher in wave of cancer vaccines

Merck and Moderna's personalized cancer vaccine shows promise for melanoma patients. This new treatment trains the immune system to target specific tumor mutations. The vaccine, combined with Keytruda, significantly reduced cancer recurrence in trials. Doctors are hopeful this approach will expand to treat many other cancer types. Further trials are…

The Economic Times · Aug 20

Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough

Elon Musk said Wednesday that mRNA technology could fundamentally change how diseases are treated, a shift that would make medicine more of a software problem than a biological one, as Moderna Inc. (NASDAQ:MRNA) and Merck & Co Inc. (NYSE:MRK) posted a major cancer-vaccine trial win.

Benzinga · Aug 20

Stocks Snap Losing Streak as Treasury Yields Ease: Stock Market Today

Yields on the 10-year and 30-year Treasuries pulled back Wednesday after the Treasury Department announced new buyback levels.

Kiplinger · Aug 19

Trump Adds to Wealth With Moderna Stock Gains: Here’s How Much President Made

Moderna Inc. (NASDAQ:MRNA) stock soared Wednesday after the company and Merck reported positive Phase 3 results for a personalized mRNA cancer vaccine, marking a major milestone for the emerging technology. Shares jumped more than 100%, reaching levels not seen since May 2024.

Benzinga · Aug 19

US stocks: US market rises as yields ease, Moderna lifts healthcare stocks

US stock markets enjoyed a boost as easing bond yields and a spike in Moderna shares contributed to a favorable trading environment. Despite the Federal Reserve's minutes highlighting inflation concerns and discussions on rate hikes, investors remained optimistic. The Treasury's announcement of liquidity support revitalized riskier assets, particularly in tech…

The Economic Times · Aug 19

'Breakthrough' mRNA cancer drug curbs melanoma in large trial

WASHINGTON (UNITED STATES) - US drugmakers Merck and Moderna said Wednesday a personalized cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a "breakthrough."

Bangkok Post · Aug 19

Breakthrough Personalized mRNA Vaccines Are Highly Effective Against Melanoma Skin Cancers

The vaccine could be available as soon as 2027.

Reason · Aug 19

Moderna's and Merck's personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

Fortune · Aug 19

Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today

U.S. equities clawed back Tuesday’s tech-led slump by midday Wednesday as the Treasury’s decision to double its long-dated debt buybacks pulled benchmark yields off 20-month highs and knocked the dollar to its weakest level since late May.

Benzinga · Aug 19